News - Novo Nordisk

Filter

Current filters:

Novo Nordisk

Popular Filters

1 to 25 of 131 results

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

31-03-2014

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration…

AlprolixBenefixBiogen IdecBiotechnologyCSL LimitedHematologyNorth AmericaNovo NordiskPfizerRegulationSwedish Orphan BiovitrumUSA

Label updates for Tresiba and Victoza backed by EMA committee

21-03-2014

The European Medicines agency’s Committee for Medicinal Products for Human Use has issued positive…

DiabetesEuropeNovo NordiskPharmaceuticalRegulationTresibaVictoza

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

19-03-2014

Danish insulin giant Novo Nordisk says it has completed the pathfinderT2, the first Phase III trial with…

HematologyN8-GPNovo NordiskPharmaceuticalResearchturoctocog alfa

Novo Nordisk invests $100 million in new purification pilot plant in Denmark

Novo Nordisk invests $100 million in new purification pilot plant in Denmark

14-03-2014

Danish insulin giant Novo Nordisk revealed this morning that it is increasing its drug development capacity…

DiabetesFinancialNovo NordiskPharmaceuticalProduction

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

05-03-2014

Danish insulin giant Novo Nordisk has presented positive data at the Diabetes UK conference from its…

DenmarkDiabetesIDegLiraNovo NordiskPharmaceuticalResearchUK

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Five big pharma firms named as high performers in annual biopharmaceutical report

Five big pharma firms named as high performers in annual biopharmaceutical report

12-02-2014

Entry in emerging markets and expedient product launches are still driving the pharma market, according…

AmgenAstellas PharmaBristol-Myers SquibbFinancialMarkets & MarketingNovo NordiskPharmaceuticalResearchRoche

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

07-02-2014

Danish insulin giant Novo Nordisk has sold full development and commercialization rights to the anti-NKG2A…

anti-NKG2AInnate PharmaLicensingMergers & AcquisitionsNovo NordiskOncologyPharmaceutical

Novo Nordisk’s profits rise 15% with further growth expected

Novo Nordisk’s profits rise 15% with further growth expected

30-01-2014

Danish insulin giant Novo Nordisk has announced a 15% growth in profit in the firm’s 2013 financial…

DenmarkDiabetesFinancialNovo NordiskPharmaceuticalTresibaVictoza

Novo Nordisk launches diabetes collaboration focused on integrated care with London partners

Novo Nordisk launches diabetes collaboration focused on integrated care with London partners

27-01-2014

A unique collaboration between leading London hospitals and Danish insulin giant Novo Nordisk (NOV: N)…

DiabetesHealthcareNovo NordiskPharmaceuticalUK

FDA approves Novo Nordisk’s Tretten to treat rare genetic clotting disorder

FDA approves Novo Nordisk’s Tretten to treat rare genetic clotting disorder

24-12-2013

The US Food and Drug Administration yesterday (December 23) approved Tretten, coagulation factor XIII…

HematologyNorth AmericaNovo NordiskNovoThirteenPharmaceuticalRare diseasesRegulationTretten

Novo Nordisk files for approval of high strength liraglutide for obesity

Novo Nordisk files for approval of high strength liraglutide for obesity

22-12-2013

Danish insulin giant Novo Nordisk has filed separate regulatory submissions with the US Food and Drug…

DiabetesEuropeliraglutideMetabolicsNorth AmericaNovo NordiskPharmaceuticalRegulationVictoza

Global insulin market expanded to $20.8 billion in 2012

17-12-2013

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular…

Asia-PacificBayerChinaDiabetesEli LillyGlobalMarkets & MarketingNovo NordiskSanofi

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

10-12-2013

Demographics favor the continued strong growth in the diabetes care market, and independent investment…

DiabetesEli LillyFinancialMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Novo Nordisk accused of delaying information release under Danish STC rules

Novo Nordisk accused of delaying information release under Danish STC rules

10-12-2013

Danish insulin giant Novo Nordisk revealed this morning that the Danish Financial Supervisory Authority…

DenmarkDiabetesEuropeFinancialLegalNovo NordiskPharmaceuticalRyzodegTresiba

Novo Nordisk’s IDegLira shows superior glycemic control and weight loss

Novo Nordisk’s IDegLira shows superior glycemic control and weight loss

03-12-2013

Danish insulin giant Novo Nordisk has presented positive new Phase III data from the investigational…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearch

Novo Nordisk aims to expand its already leading position in diabetes care

Novo Nordisk aims to expand its already leading position in diabetes care

03-12-2013

Denmark-based global insulin giant Novo Nordisk this morning set out its ambition to further expand its…

DiabetesHematologyliraglutideMetabolicsNovo NordiskOG217SCPharmaceuticalsemaglutideVictoza

EMA Committee backs Novo Nordisk’s NovoRapid PumpCart

EMA Committee backs Novo Nordisk’s NovoRapid PumpCart

22-11-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…

DiabetesEuropeNovo NordiskNovoRapidPharmaceuticalRegulationRoche

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

20-11-2013

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Novo Nordisk’s NovoEight passes first stage of Japanese approval

Novo Nordisk’s NovoEight passes first stage of Japanese approval

18-11-2013

Danish insulin giant Novo Nordisk’s recombinant factor VIII product NovoEight (turoctocog alfa) has…

Asia-PacificHematologyNovo NordiskNovoEightPharmaceuticalRare diseasesRegulation

Novo Nordisk gains US FDA approval for FlexTouch insulin pens

Novo Nordisk gains US FDA approval for FlexTouch insulin pens

03-11-2013

Danish insulin giant Novo Nordisk announced on Friday that the US Food and Drug Administration has approved…

DiabetesFlexTouchLevemirNorth AmericaNovo NordiskNovoRapidPharmaceuticalRegulation

Novo Nordisk nine-month sales up 13%; takes larger diabetes market share

Novo Nordisk nine-month sales up 13%; takes larger diabetes market share

31-10-2013

Danish insulin giant Novo Nordisk reported sales of 61.9 billion ($11.3 billion) Danish kroner in the…

DiabetesFinancialNovo NordiskPharmaceutical

Novo Nordisk recalls some NovoMix 30 insulin products in Europe

Novo Nordisk recalls some NovoMix 30 insulin products in Europe

27-10-2013

Danish insulin giant Novo Nordisk said on Friday that it is recalling certain batches of its prefilled…

DiabetesEuropeNovo NordiskNovoMixPharmaceuticalRegulation

1 to 25 of 131 results

Back to top